Related Experiment Video
Updated: Jul 17, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
The COVID-19 impact on severe uncontrolled asthma costs and biologic use
Najm S Khan1, Elizabeth Rubin2, Bernard McKenna3
1From the Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
Insights
The COVID-19 pandemic reduced healthcare costs for severe uncontrolled asthma (SUA) patients, but increased prescription expenses. Biologic therapy use also significantly declined during this period.
Area of Science:
- Pulmonary Medicine
- Health Economics
- Epidemiology
Background:
- Severe uncontrolled asthma (SUA) poses a significant economic burden and often necessitates biologic therapy.
- The impact of the COVID-19 pandemic on asthma-related costs and biologic utilization remains unevaluated.
Purpose of the Study:
- To investigate the hypothesis that costs and biologic use for severe uncontrolled asthma decreased during the COVID-19 pandemic.
Main Methods:
- Analysis of medical costs and biologic use in severe uncontrolled asthma patients from January 2017 to December 2021.
- Utilized claims data from a large managed care organization and electronic health records from Robert Wood Johnson Barnabas Health.
- Data stratified by provider specialty (primary care physicians and specialists).
Main Results:
- Total healthcare costs for severe uncontrolled asthma patients decreased during the pandemic across all care groups (34%-45% reduction).
- Inpatient and outpatient costs declined, while prescription costs increased.
- Biologic use, which was increasing pre-pandemic, saw a twofold decrease and remained low.
Conclusions:
- The COVID-19 pandemic led to decreased inpatient and outpatient costs but increased prescription costs for severe uncontrolled asthma patients.
- Biologic utilization among severe uncontrolled asthma patients significantly decreased during the pandemic and stayed reduced.
Abstract:
Background: Patients with severe uncontrolled asthma (SUA) overwhelmingly contribute to the economic burden of asthma and may require biologic therapy. However, the impact of the CoronaVirus Disease of 2019 (COVID-19) on asthma costs and biologic use has yet to be evaluated. Objective: The objective was to test the hypothesis that SUA costs and biologic use decreased during the pandemic. Methods: We analyzed medical costs and biologic use in patients with SUV from January 2017 to December 2021, by using claims data from a large managed care organization and electronic health record data from Robert Wood Johnson Barnabas Health, according to provider specialty. Results: Of the 3817 managed care organization enrollees within Robert Wood Johnson Barnabas Health with a primary diagnosis of asthma, 348 were identified as having SUA. A nested sample of 151 patients revealed that 50% were managed by primary care physicians (PCP) and specialists, 43% by PCPs only, and 4% by specialists only. The total costs of the claims were $10.8 million over 5 years ($2.2 million per year), with 60% generated from patients seeing PCPs and specialists, 27% from PCPs only, and 15% from specialists only. During the pandemic, total average costs decreased for all care groups (34% PCP-only patients and 45% for both specialist-only and PCP and specialist patients). Inpatient and outpatient costs also decreased and were lowest for patients who saw specialists and highest for patients who saw PCPs and specialists. In contrast, prescription costs increased during the pandemic. Biologic use was steadily increasing until a twofold decrease was observed during the pandemic. Thirteen patients were on biologics: two were managed by PCPs, four by specialists, and seven by both. Conclusion: Inpatient and outpatient costs decreased during the COVID-19 pandemic, but prescription costs increased. Biologic use was increasing among patients with SUA before the pandemic but then drastically decreased and remained lower during the observational interval.
More Related Videos
04:03Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
Published on: September 27, 2024
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Related Concept Videos
Asthma-III: Symptoms and Complications
Classification of Asthma
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
COPD: Management Using Bronchodilators and Corticosteroids